Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
NCT00600054
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Recurrent Diffuse Pontine Gliomas
Interventions
BIOLOGICAL:
nimotuzumab (anti EGFR humanized monoclonal antibody)
Sponsor
YM BioSciences